Zacks Research Issues Negative Outlook for Bruker Earnings

Bruker Co. (NASDAQ:BRKR) – Zacks Research dropped their Q3 2025 earnings per share (EPS) estimates for Bruker in a note issued to investors on Tuesday, November 26th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $0.72 for the quarter, down from their previous forecast of $0.94. The consensus estimate for Bruker’s current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Bruker’s Q4 2025 earnings at $0.96 EPS.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). The company had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. The company’s revenue was up 16.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.74 EPS.

Several other research analysts have also recently commented on BRKR. Barclays reduced their target price on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. TD Cowen reduced their target price on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research report on Wednesday, November 6th. Citigroup reduced their target price on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. Finally, Wells Fargo & Company reduced their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $79.36.

Bruker Trading Up 1.5 %

Shares of Bruker stock opened at $58.38 on Thursday. The company’s fifty day simple moving average is $61.02 and its 200-day simple moving average is $64.24. The company has a market cap of $8.85 billion, a price-to-earnings ratio of 28.07, a PEG ratio of 3.95 and a beta of 1.20. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24. Bruker has a 1 year low of $48.07 and a 1 year high of $94.86.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Monday, December 2nd will be paid a $0.05 dividend. The ex-dividend date of this dividend is Monday, December 2nd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.34%. Bruker’s dividend payout ratio (DPR) is presently 9.62%.

Insider Activity

In other Bruker news, CEO Frank H. Laukien bought 100,000 shares of the stock in a transaction dated Monday, November 18th. The stock was bought at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the purchase, the chief executive officer now owns 38,439,563 shares in the company, valued at $1,927,359,688.82. This represents a 0.26 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 28.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Bruker

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BRKR. Advisors Asset Management Inc. acquired a new stake in Bruker in the first quarter worth about $479,000. Lazard Asset Management LLC grew its position in shares of Bruker by 96.8% during the 1st quarter. Lazard Asset Management LLC now owns 19,771 shares of the medical research company’s stock worth $1,856,000 after buying an additional 9,724 shares during the period. Tidal Investments LLC acquired a new position in shares of Bruker during the 1st quarter worth about $218,000. Virtu Financial LLC acquired a new position in shares of Bruker during the 1st quarter worth about $251,000. Finally, Atria Investments Inc acquired a new position in shares of Bruker during the 1st quarter worth about $1,142,000. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.